نتایج جستجو برای: irinotecan

تعداد نتایج: 4284  

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016
Eva Segelov Subotheni Thavaneswaran Paul M Waring Jayesh Desai Kristy P Robledo Val J Gebski Elena Elez Louise M Nott Christos S Karapetis Sebastian Lunke Lorraine A Chantrill Nick Pavlakis Mustafa Khasraw Craig Underhill Fortunato Ciardiello Michael Jefford Harpreet Wasan Andrew Haydon Timothy J Price Guy van Hazel Kate Wilson John Simes Jeremy D Shapiro

PURPOSE RAS mutations predict lack of response to epidermal growth factor receptor monoclonal antibody therapy in patients with metastatic colorectal cancer (mCRC), but preclinical studies and retrospective clinical data suggest that patients with tumors harboring the exon 2 KRAS G13D mutation may benefit from cetuximab. We aimed to assess cetuximab monotherapy and cetuximab plus irinotecan in ...

2015
Deysi V. T. Wong Roberto C. P. Lima-Júnior Cibele B. M. Carvalho Vanessa F. Borges Carlos W. S. Wanderley Amanda X. C. Bem Caio A. V. G. Leite Maraiza A. Teixeira Gabriela L. P. Batista Rangel L. Silva Thiago M. Cunha Gerly A. C. Brito Paulo R. C. Almeida Fernando Q. Cunha Ronaldo A. Ribeiro Lena Alexopoulou

Intestinal mucositis is a common side effect of irinotecan-based anticancer regimens. Mucositis causes cell damage, bacterial/endotoxin translocation and production of cytokines including IL-1 and IL-18. These molecules and toll-like receptors (TLRs) activate a common signaling pathway that involves the Myeloid Differentiation adaptor protein, MyD88, whose role in intestinal mucositis is unknow...

2010
J Verwimp F Geurs S Ponette J Ponette J Martens K Bulté

We present the first case report of a complete response of metastatic gastroesophageal cancer in a chronic hemodialysis patient with irinotecan-based chemotherapy. An elderly dialysis patient presented with diffuse liver metastases by a gastroesophageal adenocarcinoma. He received combination chemotherapy with 5 fluorouracil and irinotecan. After six months of chemotherapy, liver scans show com...

Journal: :Oncology 2002
Claire F Verschraegen

Topoisomerase inhibitors have been widely studied for the treatment of refractory or recurrent cervical cancer. Various schedules have been used, with response rates ranging from 13% to 20%. The combination of cisplatin and irinotecan (CPT-11, Camptosar) is being studied in cervical cancer. Hematologic and gastrointestinal toxicities have been observed. Gastrointestinal toxicities have been par...

Journal: :Oncology 1998
R Pazdur

The objective response rate is the initial method to assess the activity of a novel anticancer agent. Response rates may not characterize a new agent's clinical benefit, however, especially if moderate to severe toxicity may be associated with treatment. Clinical end points, such as improvement in survival or relief of disease-related symptoms, provide clinicians with a more rational basis for ...

Journal: :The Netherlands journal of medicine 2003
W W ten Bokkel Huinink C J van Groeningen E E Voest W G Peters H J Keizer J H de Witte

BACKGROUND Irinotecan is an effective treatment for metastatic colorectal cancer. However, its use may be associated with troublesome adverse effects such as delayed diarrhoea, acute cholinergic syndrome and neutropenic infection. The manufacturer decided to release irinotecan for compassionate use in The Netherlands prior to its regulatory approval (June 1998) and first introduction for second...

Journal: :Journal of separation science 2014
Zeljko M Prijovich Pierre-Alain Burnouf Steve R Roffler

Monitoring levels of Irinotecan and its metabolites during cancer therapy could help link broad interpatient variations in antitumor activity and toxicity to the patient's metabolic status. We have developed and validated a versatile and highly sensitive method for the simultaneous determination of Irinotecan and its clinically relevant metabolites 7-ethyl-10-hydroxy-camptothecin (SN-38) and SN...

Journal: :The oncologist 2001
L B Saltz

In 1966 the plant alkaloid camptothecin was isolated and identified as an agent with promising anticancer properties. Insolubility, however, was an initial impediment to the clinical development of this agent. Phase I studies of the sodium salt of camptothecin, reported in the early 1970s, showed impressive antitumor activity, but also showed severe and unpredictable toxicities. As a result, ca...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1996
J A Houghton P J Cheshire J D Hallman L Lutz X Luo Y Li P J Houghton

Irinotecan [7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothec in] administered i.v. in two courses, each course consisting of administration every day for 5 days [(dx5)2] on days 1-5 and 8-12, has demonstrated significant activity against advanced human tumor xenografts derived from colon adenocarcinomas and several childhood cancers. To build on this therapy, we have evaluated ...

Journal: :Molecular cancer therapeutics 2014
Alastair H Kyle Jennifer H E Baker Maria-Jose Gandolfo Stefan A Reinsberg Andrew I Minchinton

The ability of a panel of camptothecin derivatives to access the tumor compartment was evaluated to determine the mechanisms by which the architecture of solid tumors may act to limit their activity. Microregional localization and activity of members of the camptothecin class of topoisomerase I targeting agents, including topotecan, irinotecan, and irinophore C, a lipid-based nanoparticulate fo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید